CSTL · NASDAQ
Castle Biosciences (CSTL) Stock Price & Fundamentals
Castle Biosciences (CSTL) closed at $682.50 on Oct 9, 2026, up 0.49% from the previous close of $679.20.
Share price, past year
1Y +14.14%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $682.50 |
| Sep 30, 2026 | $684.45 |
| Aug 31, 2026 | $697.64 |
| Jul 31, 2026 | $699.59 |
| Jun 30, 2026 | $674.74 |
| May 29, 2026 | $619.93 |
| Apr 30, 2026 | $616.61 |
| Mar 31, 2026 | $636.53 |
| Feb 27, 2026 | $652.28 |
| Jan 30, 2026 | $643.14 |
| Dec 31, 2025 | $609.62 |
| Nov 28, 2025 | $584.79 |
| Oct 31, 2025 | $576.69 |
Key statistics
- Market cap
- $20.82B
- P/E (TTM)
- —
- EPS (TTM)
- −$0.64
- Revenue (TTM)
- $357.28M
- Net income (TTM)
- −$19.42M
- Shares outstanding
- 30.5M
- Dividend yield
- —
- 52-week range
- $571.51 – $712.71
Castle Biosciences's market cap is $20.82B, based on a share price of $682.50 and 30.5M shares outstanding as of Jun 30, 2026.
Financials
Castle Biosciences reported revenue of $344.23M for fiscal 2025, up 3.66% from fiscal 2024.
Castle Biosciences reported a net loss of $24.16M in fiscal 2025.
Fiscal 2025 revenue was the highest in the 8 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $344.23M | +3.7% | −$24.16M | −7.0% | −$0.83 | $28.33M |
| FY2024ended Dec 31, 2024 | $332.07M | +51.1% | $18.25M | 5.5% | $0.62 | $36.54M |
| FY2023ended Dec 31, 2023 | $219.79M | +60.4% | −$57.47M | −26.2% | −$2.14 | −$19.25M |
| FY2022ended Dec 31, 2022 | $137.04M | +45.7% | −$67.14M | −49.0% | −$2.58 | −$47.29M |
| FY2021ended Dec 31, 2021 | $94.09M | +50.2% | −$31.29M | −33.3% | −$1.24 | −$22.47M |
| FY2020ended Dec 31, 2020 | $62.65M | +20.8% | −$10.28M | −16.4% | −$0.54 | $5.11M |
| FY2019ended Dec 31, 2019 | $51.87M | +127.6% | $5.28M | 10.2% | −$0.21 | $6.08M |
| FY2018ended Dec 31, 2018 | $22.79M | — | −$6.37M | −27.9% | −$5.33 | −$12.57M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $103.55M | −$2.06M | −$0.07 |
| Q1 FY2026ended Mar 31, 2026 | $83.68M | −$14.52M | −$0.49 |
| Q4 FY2025ended Dec 31, 2025 | $87.01M | −$2.33M | −$0.06 |
| Q3 FY2025ended Sep 30, 2025 | $83.04M | −$501.00K | −$0.02 |
| Q2 FY2025ended Jun 30, 2025 | $86.19M | $4.52M | $0.15 |
| Q1 FY2025ended Mar 31, 2025 | $87.99M | −$25.85M | −$0.90 |
| Q4 FY2024ended Dec 31, 2024 | $86.31M | $9.59M | $0.32 |
| Q3 FY2024ended Sep 30, 2024 | $85.78M | $2.27M | $0.08 |
Company profile
- Name
- Castle Biosciences, Inc.
- Ticker
- CSTL
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Services-Medical Laboratories
- Headquarters
- 1500 W. Parkwood Ave., Suite 400, Friendswood, TX 77546
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001447362
Recent SEC filings
- Jul 30, 2026
- Jul 30, 2026
- May 29, 2026
- May 6, 2026
- May 6, 2026
- Feb 26, 2026
- Feb 26, 2026
- Jan 13, 2026
Frequently asked questions
What is Castle Biosciences's stock price?
Castle Biosciences (CSTL) closed at $682.50 on Oct 9, 2026, up 0.49% from the previous close of $679.20.
What is Castle Biosciences's market cap?
Castle Biosciences's market cap is $20.82B, based on a share price of $682.50 and 30.5M shares outstanding as of Jun 30, 2026.
How much revenue does Castle Biosciences make?
Castle Biosciences reported revenue of $344.23M for fiscal 2025, up 3.66% from fiscal 2024.
Does Castle Biosciences pay a dividend?
Yes. Castle Biosciences declared $0.00 per share in dividends for fiscal 2025.
Sources and methodology
Fundamentals come from Castle Biosciences, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures